GILD

Gilead Sciences, Inc. Press Releases

$89
*  
0.79
0.9%
Get GILD Alerts
*Delayed - data as of May 2, 2016  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
3/1/2016 2:06:00 PM - Business Wire
▲0.18 % Price Change since this news event. The Volume Ratio is 1.4.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV
2/26/2016 7:52:00 AM - Business Wire
▼-1.56 % Price Change since this news event. The Volume Ratio is 1.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
2/25/2016 10:37:00 AM - Business Wire
▼-1.00 % Price Change since this news event. The Volume Ratio is 1.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
2/24/2016 12:09:00 PM - Business Wire
▲0.36 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24
2/23/2016 5:00:00 PM - Business Wire
▲0.75 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens
2/23/2016 12:10:00 PM - Business Wire
▲0.63 % Price Change since this news event. The Volume Ratio is 0.69.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


OptimizeRx Corporation Appoints William J. Febbo as CEO
2/22/2016 8:31:00 AM - Marketwired


Gilead Launches New Grants Program to Support HIV Cure
2/22/2016 8:31:00 AM - Business Wire
▲0.51 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
2/16/2016 8:30:00 AM - Business Wire
▼-1.99 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gilead Sciences to Participate in Two Upcoming Investor Conferences
2/8/2016 5:00:00 PM - Business Wire
▲4.39 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day